This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Gastrointestinal/ Upper Foregut  • Infectious Diseases  • Bacterial Infections  • Randomized Controlled Trial  • Critical Care/ Intensive Care Medicine  • Adult Critical Care  • Alert me on articles by topic

Alden H. Harken, MD

Arch Surg. 2006;141:154.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Should we be surprised when your typical personal-injury lawyer fails to achieve a much-heralded ethical epiphany in response to a single dose of "church" on a Sunday morning? Although this credibility-defying analogy may seem far fetched, the critical care community has now been deluged with a thought-suppressing smorgasbord of prospective, randomized clinical trials in which a single dose (or 2) of cytokine antibody (or binding protein) is injected into an unfortunate postinjury patient in the throes of systemic inflammation. And Lazarus dies anyway. Is this akin to confronting the raging Chicago fire by seeking out and shooting Mrs O’Leary's cow? Or air-dropping a single flame jumper into the midst of a Yellowstone National Park fire? Do all these studies really mean that our natural host defenses cannot be manipulated therapeutically?

Most of us capably stomp out 99% of our infectious challenges by means of our endogenous . . . [Full Text of this Article]

RELATED ARTICLE

Molgramostim (GM-CSF) Associated With Antibiotic Treatment in Nontraumatic Abdominal Sepsis: A Randomized, Double-blind, Placebo-Controlled Clinical Trial
Héctor Orozco, Jorge Arch, Heriberto Medina-Franco, Juan P. Pantoja, Quintín H. González, Mario Vilatoba, Carlos Hinojosa, Florencia Vargas-Vorackova, and José Sifuentes-Osornio
Arch Surg. 2006;141(2):150-153.
ABSTRACT | FULL TEXT